首页 / 院系成果 / 成果详情页

Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study 期刊论文

编号：

C9CD35A2C7ECBDDE9035D4E10B5A94F0
作者：

Chen, Fei(陈飞)#^[1,2]Zhang, GuoNan^[3];Lei, Wei^[4];Zhou, ShuGuang(周曙光)^[5]Zhang, Ying^[6];Liu, Lin^[6];Jia, Ying^[7];Xie, RongKai(谢荣凯)^[8]Tian, XiuFang^[9];Guo, Jie^[10];Yang, YueBo(杨越波)^[11]Wang, XueFeng(王雪峰)^[12]Wu, XiaoMei^[13];Sun, QiJian^[14];Zhou, Xu^[15];Lin, Yang(林杨)^[15]Zhang, YouZhong(张友忠)^[16]Ma, JunQi(马俊旗)^[17]Liu, YuXiu^[18];Cheng, YiFan(程易凡)^[19]Chen, JianCui^[20];Qu, QuanXin(瞿全新)^[21]Du, DongMei^[22];Wang, GuiYu^[22];Wang, Sheng^[22];Ling, Yu Li^[22];Wu, DaiFei^[23];Zhang, ChunFa^[23];Lang, JingHe(郎景和)*^[1,2,24]
语种：

英文
期刊：

GYNECOLOGIC ONCOLOGY ISSN：0090-8258 2023 年 178 卷 (8 - 13) ; NOV
收录：
关键词：

REBACIN Human papilloma virus (HPV) Clearance Cervical cancer Real-world study
摘要：

Background. We previously reported that REBACIN effectively eliminates persistent high-risk human papillomavirus (hrHPV) infection. Here, we conducted a prospective multicenter cohort study to evaluate the safety and effectiveness of REBACIN, taking into account factors such as specific hrHPV subtype and patient''s age. Methods. According to inclusion/exclusion criteria and participant willingness, 3252 patients were divided into REBACIN group while 249 patients into control group. Patients in REBACIN group received one course treatment of intravaginal administration of REBACIN while no treatment in control group. After drug withdrawal, participants in both groups were followed up.Results. The clearance rate of persistent hrHPV infection in REBACIN group was 60.64%, compared to 20.08% in control group. Specifically, the clearance rates for single-type infection of HPV16 or HPV18 were 70.62% and 69.23%, respectively, which was higher than that of HPV52 (59.04%) or HPV58 (62.64%). In addition, the single, double, and triple/triple+ infections had a clearance rate of 65.70%, 53.31%, and 38.30%, respectively. Moreover, 1635 patients under 40 years old had a clearance rate of 65.14%, while it was 55.08% for 1447 patients over 40 years old. No serious adverse effects were found.Conclusion. This study confirmed that REBACIN can effectively and safely eliminate persistent hrHPV infection, which the clearance rate of HPV16/18 is higher than that of HPV52/58, the clearance rate of single-type infection is higher than that of multiple-type infections, and the clearance rate in young patients is higher than that in elder patients, providing a guidance for REBACIN application in clearing hrHPV persistent infection in real -world settings.Clinical trial registration. Chinese Clinical Trial Registry Registration Number: ChiCTR1800015617 http://www.chictr.org.cn/showproj.aspx?proj=26529Date of Registration: 2018-04-11 (c) 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
推荐引用方式
GB/T 7714：

Chen Fei,Zhang Guo-Nan,Lei Wei, et al. Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study [J].GYNECOLOGIC ONCOLOGY,2023,178:8-13.
APA：

Chen Fei,Zhang Guo-Nan,Lei Wei,Zhou Shu-Guang,&Lang Jing-He.(2023).Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study .GYNECOLOGIC ONCOLOGY,178:8-13.
MLA：

Chen Fei, et al. "Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study" .GYNECOLOGIC ONCOLOGY 178(2023):8-13.
入库时间：

2023/10/21 21:50:52
更新时间：

2023/10/21 21:50:52
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：5  下载次数：0

分享到：

浏览次数：5

下载次数：0

打印次数：0